lonafarnib has been researched along with Myelomonocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barker, J; Colombat, P; Cortes, J; DeAngelo, DJ; Feldman, EJ; Frank, E; Guilhot, F; Holyoake, T; Kirschmeier, P; Lipton, JH; List, A; Loechner, S; Maloisel, F; Martinelli, G; Nielsen, JL; O'Brien, SG; Petersdorf, S; Reiffers, J; Roboz, GJ; Simonsson, B; Statkevich, P; Turner, AR; Zhu, Y | 1 |
| Buresh, A; Heaton, R; Kurtin, S; List, A; Perentesis, J; Rimsza, L; Sugrue, M | 1 |
2 trial(s) available for lonafarnib and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Drug Monitoring; Enzyme Inhibitors; Farnesyltranstransferase; Gastrointestinal Diseases; Humans; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Piperidines; Pyridines; Remission Induction; Treatment Outcome | 2008 |
Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Humans; Leukemia, Myelomonocytic, Chronic; Leukocytosis; Male; Middle Aged; Piperidines; Pyridines; Radiography, Thoracic | 2005 |